Amgen Inc. shares (NASDAQ:AMGN) briefly hit a record high of $181.81 on Friday as the drugmaker reported a higher-than-expected second quarter profit, driven in part by strong sales of Enbrel (etanercept), Prolia and Xgeva (denosumab) and cost-cutting. The drugmaker also raised its full-year guidance as it moved to launch new products, such as the world’s first approved PCSK9 inhibitor, Repatha (evolocumab).